Intriguingly, SETD4 expression correlated negatively with malignancy and immune‐related pathways including KRAS signaling, immune response, and IL2/STAT5 signaling pathways in BLCA, CHOL, and GBM, and positively in UVM. Here, SETD4 is linked to bladder transitional cell carcinoma.